DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 199 filers reported holding DENALI THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $949,021 | -28.5% | 46,002 | +2.3% | 0.00% | -20.0% |
Q2 2023 | $1,326,652 | +211.1% | 44,956 | +142.9% | 0.01% | +150.0% |
Q1 2023 | $426,401 | -26.6% | 18,507 | -11.5% | 0.00% | -33.3% |
Q4 2022 | $581,285 | -55.7% | 20,902 | -51.1% | 0.00% | -57.1% |
Q3 2022 | $1,312,000 | +1.5% | 42,741 | -2.7% | 0.01% | +16.7% |
Q2 2022 | $1,293,000 | -4.9% | 43,919 | +3.9% | 0.01% | +20.0% |
Q1 2022 | $1,359,000 | -25.9% | 42,252 | +2.8% | 0.01% | -28.6% |
Q4 2021 | $1,833,000 | -12.5% | 41,092 | -1.0% | 0.01% | -30.0% |
Q3 2021 | $2,095,000 | -20.1% | 41,522 | +24.2% | 0.01% | -16.7% |
Q2 2021 | $2,622,000 | +170.6% | 33,432 | +96.9% | 0.01% | +200.0% |
Q1 2021 | $969,000 | -45.1% | 16,975 | -19.5% | 0.00% | -50.0% |
Q4 2020 | $1,765,000 | +444.8% | 21,076 | +132.9% | 0.01% | +700.0% |
Q3 2020 | $324,000 | -15.6% | 9,051 | -43.0% | 0.00% | -50.0% |
Q2 2020 | $384,000 | +9.4% | 15,880 | -20.8% | 0.00% | 0.0% |
Q1 2020 | $351,000 | – | 20,050 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |